The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. Chief Executive Officer of Biohaven, said: “We are excited to enter into this agreement with Sosei Heptares, a world leader in GPCR drug discovery. TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

Nvidia Developer: Drug Discovery

MARCH 21, 2023

Creating new drug candidates is a heroic endeavor, often taking over 10 years to bring a drug to market. Creating new drug candidates is a heroic endeavor, often taking over 10 years to bring a drug to market. Generate small molecules with specific properties.

Small Molecule 52

Small Molecule Drugs Clinical Trials DNA 52

The Pharma Data

JUNE 22, 2023

Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan SANTA MONICA, Calif.–(BUSINESS in December 2022 about changes to their initial 2017 partnership whereby Daiichi Sankyo obtained the Marketing Authorization for Yescarta ®. –(BUSINESS WIRE)– Kite Pharma, Inc.,

Therapies 40

Therapies Marketing Small Molecule Science 40

Drug Target Review

JULY 23, 2024

This laid the groundwork for my career in drug discovery using novel modalities like small molecule inhibitors, antibodies, RNA interference (RNAi) and, currently, small molecule protein degraders – which are opportunities to change how we think about medicines.

Small Molecule 115

Small Molecule Targeted Protein Degradation Science Disease 115

ASPET

SEPTEMBER 7, 2023

Avalglucosidase alfa has received marketing authorization in several countries for infantile-onset and/or late-onset Pompe disease. This recently approved enzyme replacement therapy (ERT) was glycoengineered to maximize CIMPR binding through high-affinity interactions with ~7 bis-M6P moieties.

Small Molecule 100

Small Molecule Therapies Disease Treatment 100

Alta Sciences

AUGUST 29, 2024

Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning. billion USD in 2023 to $166.53 billion USD by 2028.

Drug Development 52

Drug Development Small Molecule Clinical Trials Drugs 52

The Premier Consulting Blog

SEPTEMBER 11, 2024

The 505(b)(2) new drug application (NDA) pathway offers a unique opportunity for small molecule developers to bring innovative products to market more efficiently by leveraging existing data they do not own or have right of reference to. The new formulation resulted in a drug product that was very viscous.

Drugs 52

Drugs Packaging Clinical Pharmacology Small Molecule 52

DrugBank

AUGUST 15, 2024

Drug development is challenging, including not only the complexities of biomolecular drug mechanisms but also the convolutions of regulatory pathways and commercialization strategies. UCSD, with its world-renowned Center for Microbiome Innovation , provides expertise in microbial genomics and drug discovery platforms.

Drug Development 81

Drug Development Clinical Trials Drugs Therapies 81

Drug Target Review

JULY 18, 2024

Why is detecting cancers via liquid biopsy before they become visible on imaging important for drug development, not just diagnostics? We believe liquid biopsy is very helpful for oncology drug development because the reduction and clearance of circulating DNA occurs quickly before radiographic imaging is available.

Drug Development 59

Drug Development Clinical Trials Drugs Vaccine 59

Conversations in Drug Development Trends

APRIL 4, 2024

Developing pharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. Stability Tests: For small molecule, only -20°C stability testing is required, while large molecule need both -20°C and -70°C tests if samples are intended for storage at these temperatures.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

The Pharma Data

JANUARY 25, 2021

.–( BUSINESS WIRE )– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. Strovel, PhD, Chief Executive Officer of Veralox Therapeutics. About VLX-1005.

FDA 52

FDA Small Molecule FDA Approval Drugs 52

The Pharma Data

AUGUST 7, 2021

Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology. The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities.

Small Molecule 52

Small Molecule Drugs Therapies Disease 52

The Pharma Data

DECEMBER 9, 2020

“Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets,” Feinberg said at the time of the launch. It’s like taking out the trash. Tranquis Therapeutics.

Marketing 52

Marketing Small Molecule Disease Pharmaceuticals 52

PerkinElmer

JANUARY 21, 2021

Using drugs that are already on the market was the quickest path forward to evaluate these compounds and possibly help patients now because novel drug development typically takes years. Scientists needed to evaluate the field of potential drugs-and fast. It is, therefore, a tricky target for drugs.

Treatment 52

Treatment Small Molecule Drugs Virus 52

LifeSciVC

JANUARY 16, 2024

The market for each target class likely asymptotes with the number of Pharma or large biotech who can clinically develop and commercialize such assets; thus, there is intense focus on the first handful of assets to market. Small molecule GLP1s?

Small Molecule 139

Small Molecule Trials Therapies Disease 139

The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. These evaluations include the active pharmaceutical ingredient (API), also known as the drug substance, and the drug product (formulated product).

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

The Pharma Data

OCTOBER 4, 2021

In a recent paper, researchers at GlaxoSmithKline (GSK) and the Cambridge Crystallographic Data Centre (CCDC) combined their proprietary (GSK) and published (CCDC) datasets to better train machine learning (ML) models to predict stable polymorphs to use in new drug candidates. What are the key differences between the CCDC and GSK datasets?

Small Molecule 52

Small Molecule Drugs Pharmaceuticals Research 52

The Pharma Data

NOVEMBER 29, 2020

(Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ?-synuclein synuclein for the potential treatment of synucleinopathies including Parkinson’s disease and dementia with Lewy bodies.

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

Practical Cheminformatics

JANUARY 8, 2024

Picking up where we left off in Part I , this post covers several other ML in drug discovery topics that interested me in 2023. Most of the LLM activity in the drug discovery space in 2023 was reported as preprints from academic groups. Most of the drug discovery examples were underwhelming. Here’s the structure of Part II.

Drugs 141

Drugs Small Molecule Bioinformatics Packaging 141

New Drug Approvals

OCTOBER 12, 2024

After tramiprosate failed in Phase 3, its maker, NeuroChem, marketed it as a nutritional supplement. A more recent study found that homotaurine activates GABA receptors, and suggests an alternative mechanism of action for ALZ-801 ( Meera et al., 2016 ; Abushakra et al., 2016 ; Abushakra et al., Hey, et al. 2018; 32(9): 849–861. [2].

Pharmacokinetics 62

Pharmacokinetics Small Molecule Disease Licensing 62

The Premier Consulting Blog

JULY 31, 2024

In this blog, we explain the role of clinical pharmacology in drug development and demonstrate how the right strategy can accelerate development under the US Food and Drug Administration (FDA) 505(b)(1) and 505(b)(2) New Drug Application (NDA) pathways.

Clinical Pharmacology 52

Clinical Pharmacology Drug Development Pharmacokinetics Drugs 52

PPD

OCTOBER 18, 2023

As exponential growth and global expansion continue in both the biotech and pharmaceutical industries, it is critical for drug development companies to partner with good manufacturing practices (GMP) / chemistry manufacturing and controls (CMC) contract labs to conduct analyses of a range of small molecules and biologics and drive therapies forward (..)

Laboratories 52

Laboratories Assay Development Small Molecule Drug Development 52

LifeSciVC

AUGUST 5, 2024

We are constantly reminded how we are in the midst of an artificial intelligence revolution of the drug development process which promises to completely transform how we develop drugs with increases in productivity of an order of magnitude or more. a company with the strongest pipeline in the entire industry.”

Molecular Biology 87

Molecular Biology Production Drug Development Small Molecule 87

Drug Target Review

JULY 18, 2023

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. Cavlan notes that underpinning this use of AI in early discovery is the need to better understand biology.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

Metabolite Tales Blog

NOVEMBER 13, 2024

Our paper pick this month and latest blog describes the routes of biotransformation of Cytokinetics’ aficamten, a drug mainly eliminated by metabolism [1,2]. It’s hypothesized that any parent drug might also be degraded in the intestine to M18. Drug Metabolism and Disposition April 1, 2020, 48 (4) 317-325; DOI: [link]. [5]

Pharmacokinetics 52

Pharmacokinetics Small Molecule Production Clinical Development 52

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Drug Target Review

JUNE 19, 2024

Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy. Just like small molecules and antibodies, cell therapies are changing how we treat patients. from May 2017 until December 2022.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Metabolite Tales Blog

MAY 12, 2023

Breaking C-F bonds in drugs – metabolism mediated release of fluorine By Samuel Coe and Julia Shanu-Wilson Lenacapavir, recently approved for multi-drug resistant HIV-1 infection, contains 10 fluorine atoms. Increasingly used in drug design, some drug structures are now bristling with fluorine atoms.

Drugs 52

Drugs Small Molecule FDA Approval Metabolic Stability 52

LifeSciVC

APRIL 24, 2024

Is a novel target at the inflection point where enough evidence is available to suggest it may prove to be a compelling drug? and whether a molecule’s pharmacology can help to mitigate safety risk. In order to start building a case for or against a target, I like to start with genetics – first human and then mouse. in liver, in CNS)?

Production 114

Production Small Molecule Regulations Trials 114

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

PerkinElmer

SEPTEMBER 8, 2019

Over the last 20 years, Cisbio has become a leading Life Sciences company which develops, manufactures, and markets high quality kits and reagents for the drug discovery and life science markets used by pharmaceutical, biotechnology, academia and contract research organizations across the globe. Learn more about Cisbio here.

Cell Based Assays 52

Cell Based Assays Small Molecule Science Pharmaceuticals 52

The Pharma Data

JANUARY 13, 2021

PITTSBURGH–( BUSINESS WIRE )– Knopp Biosciences LLC today announced positive top-line results in a Phase 2 dose-ranging trial of the novel oral drug dexpramipexole in patients with moderate-to-severe eosinophilic asthma. Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

Agency IQ

NOVEMBER 10, 2023

To address these data gaps, OPQ is intended to provide FDA insight on quality throughout the lifecycle of products including new drugs, generics, and over-the-counter medications. What the offices will focus on: OPQA I and II are set to focus on small-molecule product assessments.

Pharmaceuticals 40

Pharmaceuticals Small Molecule Science FDA 40

Creative Biolabs

JUNE 29, 2023

According to statistics, 103 GPCRs currently have clinically used drugs for various diseases. And among the drugs currently under development, there are 142 compounds targeting 83 different GPCRs. GPCR is the most valuable target for drug development, and more drugs will be used to treat various diseases in the future.

Therapies 52

Therapies Small Molecule Drugs Drug Development 52

The Pharma Data

NOVEMBER 26, 2020

As drug molecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. HELSINKI , Nov. ” Prof.

Small Molecule 52

Small Molecule Clinical Trials Marketing Pharmaceuticals 52

Drug Target Review

DECEMBER 21, 2023

mRNA biology has become widely recognised as a new “drug mine” RNAi drugs are in the market and mRNA vaccines, initially developed for Covid-19, are already in trials for cancer. All of these are novel targets to be explored in small molecule drug discovery as well as for improving the efficacy of mRNA vaccines.

Disease 105

Disease Small Molecule Vaccine Drugs 105

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. PSMA is highly expressed on the surface of prostate cancer cells and has been demonstrated to be a validated target for precision anti-cancer drugs.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52